Hum. Reprod. Advance Access published online on June 15, 2005
Human Reproduction, doi:10.1093/humrep/dei120
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Oncogenetic Laboratory, Department of Internal Medicine ‘A’
* To whom correspondence should be addressed. BACKGROUND: Statins inhibit 3-hydroxy-3-methylglutaryl coenzyme-A reductase (HMG-CoA reductase), the rate-limiting enzyme of the mevalonate pathway, and have been used successfully in the treatment of hypercholesterolaemia. Animal models have provided evidence for the teratogenic effects of statins on pregnancy outcome. Thus statins are contraindicated during pregnancy. However, conflicting data are available from inadvertent use of statins in human pregnancy. Therefore we decided to explore the effects of simvastatin on the placenta in an in vitro human placental model. METHODS: Human first trimester placental explants that were grown on matrigel were exposed to medium supplemented with simvastatin. Migration of extravillous trophoblast cells was assessed by visual observation. Proliferative and apoptotic events of the trophoblast cells were assesed by immunohistochemical examination using anti-Ki67 and anti-activated caspase-3 antibodies respectively. Hormone levels were measured. RESULTS: Simvastatin sharply inhibited migration of extravillous trophoblast cells from the villi to the matrigel (P < 0.05). Moreover, simvastatin inhibited half of the proliferative events in the villi (P < 0.05) and increased apoptosis of cytotrophoblast cells compared to control. Moreover, simvastatin significantly decreased secretion of progesterone from the placental explants (P < 0.01). CONCLUSION: Simvastatin adversely affects human first trimester trophoblast.
Received April 12, 2005
Accepted May 6, 2005
Article
Simvastatin has deleterious effects on human first trimester placental explants
2 Department of Internal Medicine ‘F’
3 Department of Obstetrics & Gynecology, Sapir Medical Center, Kfar-Saba
4 Oncogenetic Laboratory, Department of Internal Medicine ‘A’; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
S. Tartakover-Matalon, E-mail: matalon.shelly{at}clalit.org.il
![]()
Abstract ![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
M. Kendrick Should women be offered cholesterol lowering drugs to prevent cardiovascular disease? No BMJ, May 12, 2007; 334(7601): 983 - 983. [Full Text] [PDF] |
||||
![]() |
S. Tartakover-Matalon, N. Cherepnin, M. Kuchuk, L. Drucker, I. Kenis, A. Fishman, M. Pomeranz, and M. Lishner Impaired migration of trophoblast cells caused by simvastatin is associated with decreased membrane IGF-I receptor, MMP2 activity and HSP27 expression Hum. Reprod., April 1, 2007; 22(4): 1161 - 1167. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. R Murphy, R. C Temple, and J. M Roland Improving outcomes of pregnancy for women with type 1 and type 2 diabetes The British Journal of Diabetes & Vascular Disease, January 1, 2007; 7(1): 38 - 42. [Abstract] [PDF] |
||||


